TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27482750

Group type: COMPARATOR
Intervention: Placebo gel (Castrate)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1.25 g testosterone gel (Low T/E)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5 g testosterone gel (Normal T/E)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 5 g testosterone gel with letrozole (Normal T/Low E)
Number of subjects: 56
Study: 25274220

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 23235130

Group type: EXPERIMENTAL
Intervention: Daily chewing gum containing xylitol (A)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol (B)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol (C)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (D) - children of mothers with low counts of salivary mutans streptococci
Number of subjects: 173
Study: 20202160

Group type: EXPERIMENTAL
Intervention: 0.25% thiazone and 5‐min ultrasound (0.25%T/SP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 (PEG400)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% thiazone (0.25%T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study: 18818563

Group type: EXPERIMENTAL
Intervention: Light needling acupuncture on point LI4 on both hands for approximately 20 seconds on four occasions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (same care except needling)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Light needling acupuncture
Number of subjects: 40
Study: 15768203

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 0
Study: 12467070

Group type: EXPERIMENTAL
Intervention: Liposomal tretinoin administered three times weekly
Number of subjects: 76

Group type: COMPARATOR
Intervention: Liposomal tretinoin administered once weekly
Number of subjects: 76
Study: 10840537

Group type: EXPERIMENTAL
Intervention: aprotinin (high-dose-scheme)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tranexamic acid (2 g/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: no antifibrinolytic therapy (control group)
Number of subjects: 60
Study: 8690552

Group type: EXPERIMENTAL
Intervention: Expert panel assessment of gain in life expectancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert panel assessment of gain in quality of life
Number of subjects: 0
Study: 1854445

Group type: EXPERIMENTAL
Intervention: Fluoride/triclosan/copolymer dentifrice (0.3% triclosan, 2.0% copolymer, 0.243% sodium fluoride/silica base)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride in silica base)
Number of subjects: 70
Study: 6662766

Group type: EXPERIMENTAL
Intervention: 75 g fructose (F)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 75 g glucose (G)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study: 31764468

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous-intensity physical activity (MVPA) 150-300 min/week
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous-intensity physical activity (MVPA) >300 min/week
Number of subjects: 346

Group type: COMPARATOR
Intervention: Moderate to vigorous-intensity physical activity (MVPA) <150 min/week
Number of subjects: 346
Study: 29394188

Group type: EXPERIMENTAL
Intervention: Twice weekly low‐to‐moderate intensity resistance training
Number of subjects: 134

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 134

Group type: COMPARATOR
Intervention: Bimonthly pregnancy education classes
Number of subjects: 134
Study: 26206077

Group type: EXPERIMENTAL
Intervention: 5-day aprepitant
Number of subjects: 93

Group type: COMPARATOR
Intervention: Single administration of fosaprepitant meglumine
Number of subjects: 93
Study: 24990067

Group type: EXPERIMENTAL
Intervention: Levobupivacaine infiltration (75 mg/30 cc)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline infiltration (30 cc)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 22209796

Group type: EXPERIMENTAL
Intervention: High-frequency TENS (HF-TENS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo TENS (P-TENS)
Number of subjects: 27
Study: 20560029

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of CD133(+) bone marrow stem cells
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17654129

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (Seretide) 50/250 microg twice daily (SFC)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Fluticasone propionate (Flixotide) 250 microg twice daily (FP)
Number of subjects: 362
Study: 15857224

Group type: EXPERIMENTAL
Intervention: Single-wave bolus (100% of insulin given immediately)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4-h dual-wave bolus (50% of insulin given immediately and 50% given over a 4-h period)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8-h dual-wave bolus (50% of insulin given immediately and 50% given over a 8-h period)
Number of subjects: 24
Study: 12145009

Group type: EXPERIMENTAL
Intervention: High-isoflavone diet (56 mg isoflavones/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-isoflavone diet (2 mg isoflavones/d)
Number of subjects: 22
Study: 10442277

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 124

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 124
Study: 8568190

Group type: EXPERIMENTAL
Intervention: Water-insoluble carob fraction (FIC, 1970 mg every 2 hours for 48 hours)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 2203481

Group type: EXPERIMENTAL
Intervention: Prednisone administered from day 0 through 35 along with methotrexate/cyclosporine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Methotrexate/cyclosporine without prednisone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Methotrexate/cyclosporine along with 'late' prednisone starting on day 15
Number of subjects: 147
Study: 1266576

Group type: EXPERIMENTAL
Intervention: levodopa + carbidopa (Sinemet)
Number of subjects: 92

Group type: COMPARATOR
Intervention: levodopa + benserazide (Madopar)
Number of subjects: 92
Study: 31692016

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg, 4 times daily for 4 days)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 31738716

Group type: EXPERIMENTAL
Intervention: Four-hour BBN simulation-based training (training group, n = 37)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 160-hour ED clinical rotation without a formal BBN curriculum (control group, n = 31)
Number of subjects: 68
Study: 28236512

Group type: EXPERIMENTAL
Intervention: Recovery coach for parents (experimental group)
Number of subjects: 3440

Group type: COMPARATOR
Intervention: Services as usual (control group)
Number of subjects: 3440
Study: 25333793

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of a culturally tailored video about HPV, cervical cancer, Self‐HPV and its relevancy as a screening test.
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard information (control group) including explanations about what the test detects (HPV), the link between HPV and cervical cancer and how to perform HPV self‐sampling.
Number of subjects: 302
Study: 24356755

Group type: EXPERIMENTAL
Intervention: Moderate Sedation (MS) using TCI-delivered propofol and remifentanil
Number of subjects: 92

Group type: COMPARATOR
Intervention: General Anesthesia (GA) using TCI-delivered propofol and remifentanil with HFJV
Number of subjects: 92
Study: 20593742

Group type: EXPERIMENTAL
Intervention: Oral galantamine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch
Number of subjects: 84
Study: 18287179

Group type: EXPERIMENTAL
Intervention: Pravastatin + vitamin E + homocysteine-lowering B-vitamin therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 17194264

Group type: EXPERIMENTAL
Intervention: Active TMS treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Active TMS treatment with stimulation intensity below 90% of motor threshold
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Active TMS treatment with new medication starting within 7 days before to 7 days after start of TMS
Number of subjects: 33
Study: 14568368

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program (n=15)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Educational advice (Control group, n=8)
Number of subjects: 23
Study: 11069333

Group type: EXPERIMENTAL
Intervention: Nasal first/oral second group (10 nasal intubations followed by 10 oral intubations)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral first/nasal second group (10 oral intubations followed by 10 nasal intubations)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nasal first/oral second group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral first/nasal second group
Number of subjects: 30
Study: 9118715

Group type: EXPERIMENTAL
Intervention: Inhaled and systemic corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 0
Study: 7917772

Group type: EXPERIMENTAL
Intervention: Single oral doses of lazabemide (100‐300 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of lazabemide (100‐350 mg 12 hourly for 7 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Single and multiple dosing of lazabemide
Number of subjects: 75
Study: 3288016

Group type: EXPERIMENTAL
Intervention: Ergot alkaloid (co-dergocrine mesylate) 3 x 2 mg/day for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (slow-release formulation) 3 x 400 mg/day for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard basic therapy (control group)
Number of subjects: 90
Study: 31379380

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 30 weekly sessions
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 58
Study: 28744115

Group type: EXPERIMENTAL
Intervention: GB 12.5 μg BID
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GB 25 μg BID
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: GB 50 μg BID
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 38
Study: 28665378

Group type: EXPERIMENTAL
Intervention: General magnetic therapy in addition to initial therapy (medication, therapeutic physical exercises, aquatic therapy)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (initial therapy only)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: General magnetic therapy
Number of subjects: 73
Study: 24070098

Group type: EXPERIMENTAL
Intervention: HEART score calculation to guide clinical decision
Number of subjects: 6600
Study: 21378715

Group type: EXPERIMENTAL
Intervention: Chewing gums with stevioside (1.25% and 2.5%)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (a basis without additives)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Chewing sweets R.O.C.S. and other gums with sugar substitutes (xylitol, sorbitol)
Number of subjects: 126
Study: 19675744

Group type: EXPERIMENTAL
Intervention: Oral 5‐FU at a dose of 1250 mg/qm(2) twice a day for two weeks, then paused for a week, restarted; oral thalidomide at a maximum dose of 400 mg/d for three months
Number of subjects: 12
Study: 17170202

Group type: EXPERIMENTAL
Intervention: Hyperoxic training (60% O2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 9
Study: 15709454

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Active treatment groups (Levalbuterol and Racemic Albuterol)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Racemic Albuterol
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 362
Study: 11470011

Group type: EXPERIMENTAL
Intervention: Calcium antagonist therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diuretic and beta-blocker therapy
Number of subjects: 0
Study: 8635924

Group type: EXPERIMENTAL
Intervention: Oral feeding with a nasogastric tube
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral feeding without a nasogastric tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Presence of nasogastric tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transition from tube feedings to oral feedings
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desaturation events
Number of subjects: 20
Study: 1617923

Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg once daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Doxycycline (200 mg once daily)
Number of subjects: 76
Study: 4051323

Group type: EXPERIMENTAL
Intervention: 0.12 ppm O3 exposure
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 23
Study: 29400630

Group type: EXPERIMENTAL
Intervention: Physical activity buddy program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Inactive buddies
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Active buddies
Number of subjects: 49
Study: 30864756

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (62.34% of cases)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Physician practices
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Educational health programs
Number of subjects: 908
Study: 26483255

Group type: EXPERIMENTAL
Intervention: MBDA scores (scale 1‐100)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: ACPA status
Number of subjects: 94
Study: 24760259

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (5,000 IU daily)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Low-dose vitamin D supplementation (400 IU daily)
Number of subjects: 179
Study: 24047015

Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: iv oxytocin
Number of subjects: 72
Study: 19295225

Group type: EXPERIMENTAL
Intervention: Antimony 6x
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17264104

Group type: EXPERIMENTAL
Intervention: Group tai chi sessions (40 min/session, 3 times a week for 6 weeks) followed by home-based tai chi training (6 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Attention control group (health lectures for 6 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group tai chi sessions
Number of subjects: 41
Study: 15650978

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: TEA and amiodarone
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 163
Study: 11239859

Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine (5%) solution applied 10 and 5 minutes before surgery and vancomycin (20 microg/ml) in the irrigating fluid
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Vancomycin (20 microg/ml) in the irrigating fluid
Number of subjects: 400

Group type: COMPARATOR
Intervention: Topical placebo solution and irrigating fluid only without antibiotics
Number of subjects: 400
Study: 9651405

Group type: EXPERIMENTAL
Intervention: 10 mg of elemental zinc daily for 6 months
Number of subjects: 609

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 609
Study: 9828781

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late surgery
Number of subjects: 0
Study: 2198296

Group type: EXPERIMENTAL
Intervention: Zolpidem, an imidazopyridine hypnotic compound
Number of subjects: 0
Study: 714200

Group type: EXPERIMENTAL
Intervention: Chlorthiazide (500 mg twice a day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chlorthiazide (500 mg twice a day) + Propranolol (10‐‐20 mg 4 times a day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 15
Study: 31868538

Group type: EXPERIMENTAL
Intervention: Associative learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrinsic value system
Number of subjects: 0
Study: 31344751

Group type: EXPERIMENTAL
Intervention: Family-based treatment for paediatric obesity (FBT-PO)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nutrition education counselling (NEC)
Number of subjects: 77
Study: 28079396

Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 7 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo supplementation for 7 days
Number of subjects: 67
Study: 25684604

Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg once daily
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 605

Group type: COMPARATOR
Intervention: Reference subject (67 kg)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Gender, age, and country
Number of subjects: 605
Study: 23642977

Group type: EXPERIMENTAL
Intervention: Psycho-education along with pharmacotherapy treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 108
Study: 21285531

Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted formulation containing 7.5 μg antigen
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted formulations containing 15 or 30 μg antigen
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: MF59®-adjuvanted vaccine
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: All vaccines (including both adjuvanted and non-adjuvanted)
Number of subjects: 392
Study: 19856243

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoterol (pulsatile administration)
Number of subjects: 0
Study: 16886936

Group type: EXPERIMENTAL
Intervention: VIP (8 pmol/kg per min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study: 14760339

Group type: EXPERIMENTAL
Intervention: 250 mL of red wine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 250 mL of dealcoholized red wine
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1 cigarette (smoking only)
Number of subjects: 16
Study: 11740417

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (UFH) - 5000 units s.c. x 3 daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - calcium nadroparin, single daily dose of 0.3 ml s.c.
Number of subjects: 50
Study: 8976223

Group type: EXPERIMENTAL
Intervention: 2% lidocaine jelly
Number of subjects: 179

Group type: COMPARATOR
Intervention: Plain lubricant
Number of subjects: 179
Study: 8116325

Group type: EXPERIMENTAL
Intervention: Propacetamol 2 g every 6 hours for 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline every 6 hours for 24 hours (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Piritramide administration in both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propacetamol given from 12 hours after surgery
Number of subjects: 40
Study: 3311480

Group type: EXPERIMENTAL
Intervention: Cortisone treatment (50 mg orally twice daily for 4 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (absence of any medication)
Number of subjects: 8
Study: 29125901

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg once a day
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 28528120

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes Mellitus (DM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy children (Control)
Number of subjects: 56
Study: 26537948

Group type: EXPERIMENTAL
Intervention: Septoplasty (with or without concurrent turbinate surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-surgical management (watchful waiting strategy)
Number of subjects: 200
Study: 22643040

Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pure laparoscopic abdominal sacrocolpopexy (LASC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: RASC
Number of subjects: 64

Group type: COMPARATOR
Intervention: LASC
Number of subjects: 64
Study: 20395857

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (observed for 6 months)
Number of subjects: 18
Study: 18545210

Group type: COMPARATOR
Intervention: Circuit training (S)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endurance before circuit training (E+S)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Circuit before endurance training (S+E)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No training (C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance-type circuit training (weeks 1-6)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance-type circuit training (weeks 7-12)
Number of subjects: 48
Study: 15961424

Group type: EXPERIMENTAL
Intervention: Air dive at 280 kPa for 80 min
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oxygen breathing (60% oxygen) at 280 kPa for 80 min
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal controls (no diving)
Number of subjects: 21
Study: 12714348

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo nebulization
Number of subjects: 18
Study: 10482088

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% topically twice daily for 29 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 28
Study: 8735778

Group type: EXPERIMENTAL
Intervention: 1 g of vitamin C for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 16